Centers for Disease Control and Prevention
 CDC Home Search Health Topics A-Z

DES Home | For Consumers | For Health Care Providers
For DES Update Partners | Contact Us
DES Update: Health Care Providers
DES Update: Health Care Providers

Notice! Content may be out of date
The following content is no longer maintained and may be out of date. Persons with disabilities having difficulty accessing the information on this page may contact cdcinfo@cdc.gov for assistance. Please view the Updated Bibliographies on the Updated Bibliographies page for updated information on this topic.



 Health Care Providers Home
 Information to Identify and Manage DES Patients
 Supplemental DES Materials for Nurses
 Pharmacology
 DES Brand Names
 Resources and Educational Tools
 DES References
 References By Number
 References By Topic

Email this page
Order DES materials
Image of a book with a page being turned  DES References
Health Care Providers Home > DES References > 101 - 200
DES References 101 - 200

References By Number

 References 1 - 100
 References 101 - 200
 References 201 - 297

101. Palmer JR, Hatch EE, Rao S, Kaufman RH, Herbst AL, Noller KL, et al. Infertility among women exposed prenatally to diethylstilbestrol. Am J Epidemiol 2001;154:319-21.

102. Pillsbury SG. Reproductive significance of changes in the endometrial cavity associated with exposure in utero to diethylstilbestrol. Am J Obstet Gynecol 1980;137(2):178-82.

103. Rosenfeld DL, Bronson RA. Reproductive problems in the DES-exposed female. Obstet Gynecol 1980;55(4):453-6.

104. Rusch RW, Isaccs S, McPherson K, Jones L, Chalmers I, Grant A. A randomized controlled trial of cervical cerclage in women at high risk of spontaneous preterm delivery. Br J Obstet Gynaecol 1984;91:724-30.

105. Sandberg EC, Riffle NL, Higdon JV, Getman CE. Pregnancy outcome in women exposed to diethylstilbestrol in utero. Am J Obstet Gynecol 1981;140:194-205.

106. Schmidt G, Fowler WC Jr, Talbert LM, Edelman DA. Reproductive history of women exposed to diethylstilbestrol in utero. Fertil Steril 1980;33(1):21-4.

107. Seigler AM, Wang CF, Friberg J. Fertility of the diethylstilbestrol exposed offspring. Fertil Steril 1979;31:601-7.

108. Senekjian EK, Potkul RK, Frey K, Herbst AL. Infertility among daughters either exposed or not exposed to diethylstilbestrol. Am J Obstet Gynecol 1988;158(3 pt 1):493-8.

109. Singer MS, Hochman M. Incompetent cervix in a hormone-exposed offspring. Obstet Gynecol 1978;51:625-6.

110. Stillman RJ. In utero exposure to diethylstilbestrol: Adverse effects on the reproductive tract and reproductive performance in male and female offspring [review]. Am J Obstet Gynecol 1982;142:905-21.

111. Thorp JM Jr, Fowler WC, Donehoo R, Sawicki C, Bowes WA Jr. Antepartum and intrapartum events in women exposed in utero to diethylstilbestrol. Obstet Gynecol 1990;76(5 pt 1):828-32.

112. Veridiano NP, Delke I, Rogers J, Tancer ML. Reproductive performance of DES-exposed female progeny. Obstet Gynecol 1981;58:58-61.

113. Adam E, Decker DG, Herbst AL, Noller KL, Tilley BC, Townsend DE. Vaginal and cervical cancers and other abnormalities associated with exposure in utero to diethylstilbestrol and related synthetic hormones. Cancer Res 1977;37(4):1249-51.

114. Anderson B, Watring WG, Edinger DD Jr, Small EC, Netland AT, Safaii H. Development of DES-associated clear cell carcinoma: the importance of regular screening. Obstet Gynecol 1979;53(3):293-9.

115. Burks RJ, Schwartz AM, Wheeler JE, Antonioli D. Late recurrence of clear-cell adenocarcinoma of the cervix [case report]. Obstet Gynecol 1990;76(3 pt 2):525-7.

116. Carlson JA Jr, Morgan M, Boothby R, Rubin M. Stage II papillary clear cell adenocarcinoma of the vagina during observation in a diethylstilbestrol-exposed daughter. Gynecol Oncol 1989;32(1):86-7.

117. Clark LC, Portier KM. Diethylstilbestrol and the risk of cancer. N Eng J Med 1979;300(5):263-4.

118. Davis JA, Wadehra V, McIntosh AS, Monaghan JM. A case of clear cell adenocarcinoma of the vagina in pregnancy [case report]. Br J Obstet Gynaecol 1981;88(3):322-6.

119. Dewhurst J, Ferreira HP, Dally VM, Staffurth JF. Stilboestrol-associated vaginal carcinoma treated by radiotherapy [case report]. J Obstet Gynecol 1980;1:63-4.

120. Dickersin GR, Welch WR, Erlandson R, Robboy SJ. Ultrastructure of 16 cases of clear cell adenocarcinoma of the vagina and cervix in young women. Cancer 1980;45(7):1615-24.

121. Edelman DA. Diethylstilbestrol exposure and the risk of clear cell cervical and vaginal adenocarcinoma. Int J Fertil 1989;34(4):251-5.

122. Eisenfeld AJ, Schwartz PE, Morris JM. Estrogen and progesterone receptors in vaginal and uterine adenocarcinomas following estrogen use [case report]. Gynecol Oncol 1980;10(1):63-8.

123. Forsberg JG. Diethylstilbestrol, clear cell adenocarcinoma, and striking discoveries in Norway. Am J Med 1988;84(1):184.

124. Fowler WC Jr, Schmidt G, Edelman DA, Kaufman DG, Fenoglio CM. Risks of cervical intraepithelial neoplasia among DES-exposed progeny. Obstet Gynecol 1981;58(6):720-4.

125. Ghosh TK, Cera PJ. Transition of benign vaginal adenosis to clear cell carcinoma. Obstet Gynecol 1983;61(1):126-30.

126. Goodman A, Sullinger JC, Rice LW, Fuller AF Jr. Clear cell adenocarcinoma of the vagina: a second primary in a diethylstilbestrol-exposed woman [case report] Gynecol Oncology 1991;43(2):173-7.

127. Greenwald P, Nasca PC, Burnett WS, Polan A. Prenatal stilbestrol experience of mothers of young cancer patients. Cancer 1973;31:568-72.

128. Greenwald P, Barlow JJ, Nasca PC, Burnett WS. Vaginal cancer after maternal treatment with synthetic estrogens. N Engl J Med 1971;285:390-2.

129. Hanselaar AG, Leusen ND, DeWilde PC, Vooijs GP. Clear cell adenocarcinoma of the vagina and cervix: A report of the Central Netherlands Registry with emphasis on early detection and prognosis. Cancer 1991;67(7):1971-8.

130. Herbst AL, Anderson D. Clear cell adenocarcinoma of the vagina and cervix secondary to intrauterine exposure to diethylstilbestrol. Semin Surg Oncol 1990;6(6):343-6.

131. Herbst AL. The effects in the human of diethylstilbestrol (DES) use during pregnancy [review]. Int Symp Princess Takamatsu Cancer Res Fund 1987;18:67-75.

132. Herbst AL, Ulfelder H, Poskanzer DC. Adenocarcinoma of the vagina: association of maternal stilbestrol therapy with tumor appearance in young women. N Engl J Med 1971;284:878-81.

133. Herbst AL. Diethylstilbestrol and other sex hormones during pregnancy [review]. Obstet Gynecol 1981;58:25S-40S.

134. Herbst AL. The epidemiology of vaginal and cervical cancer clear cell adenocarcinoma [review]. In: Herbst AL, Bern HA, editors. Developmental effects of diethylstilbestrol (DES) in pregnancy. New York: Thieme-Stratton, Inc.; 1981. Chapter 5.

135. Herbst AL. Clear cell adnocarcinoma and the current status of DES-exposed females. Cancer 1981;48(2 Suppl):484-8.

136. Herbst AL, Poskanzer DC, Robboy SJ, Friedlander L, Scully RE. Prenatal exposure to stilbestrol: a prospective comparison of exposed female offspring with unexposed controls. N Engl J Med 1975;292:334-9.

137. Herbst AL, Anderson S, Hubby MM, Haenszel WM, Kaufman RH, Noller KL. Risk factors for the development of diethylstilbestrol-associated clear cell adenocarcinoma: a case-control study. Am J Obstet Gynecol 1986;154(4):814-22.

138. Herbst AL, Scully RE. Adenocarcinoma of the vagina in adolescence: a report of 7 cases including 6 clear cell carcinomas (so-called mesonephromas). Cancer 1970;25:745.

139. Herbst AL, Kurman RJ, Scully RE, Poskanzer DC. Clear cell adenocarcinoma of the genital tract in young females: Registry report. N Engl J Med 1972;287:1259-64.

140. Herbst AL, Kurman RJ, Scully RE. Vaginal and cervical abnormalities after exposure to stilbestrol in utero. Obstet Gynecol 1972;40:287.

141. Herbst AL, Robboy SJ, Scully RE, Poskanzer DC. Clear cell adenocarcinoma of the vagina and cervix in young females: an analysis of 170 Registry cases. Am J Obstet Gynecol 1974;119:713-23.

142. Herbst AL, Cole P, Colton T, Robboy SJ, Scully RE. Age-incidence and risk of diethylstilbestrol-related clear cell adenocarcinoma of the vagina and cervix. Am J Obstet Gynecol 1977;128:43-50.

143. Herbst AL, Cole P, Norusis MJ, Welch WR, Scully RE. Epidemiologic aspects and factors related to survival in 384 cases of clear cell adenocarcinoma of the vagina and cervix. Am J Obstet Gynecol 1979;135:876.

144. Herbst AL, Norusis MJ, Rosenow PJ, Welch WR, Scully RE. An analysis of 346 cases of clear cell adenocarcinoma of the vagina and cervix with emphasis on recurrence and survival. Gynecol Oncol 1979;7:111-2.

145. Hoover R, Fraumeni JF Jr. Drug-induced cancer [review]. Cancer 1981;47(5 Suppl):S1071-S80.

146. Horwitz RI, Viscoli CM, Merino M, Brennan TA, Flannery JT, Robboy SJ. Clear-cell adenocarcinoma of the vagina and cervix: incidence, undetected disease and diethylstilbestrol. J Clin Epidemiol 1988;41(6):593-7.

147. Hudson CN, Crandon AJ, Baird PJ, Willcocks D. Preservation of reproductive potential in diethylstilbestrol-related vaginal adenocarcinoma. Am J Obstet Gynecol 1983;145(3):375-7.

148. Jones WB, Koulos JP, Saigo PE, Lewis JL Jr. Clear-cell adenocarcinoma of the lower genital tract: Memorial Hospital 1974-1984. Obstet Gynecol 1987;70(4):573-7.

149. Jones WB, Woodruff JM, Erlandson RA, Lewis JL Jr. DES-related clear cell adenocarcinoma of the vagina in pregnancy. Obstet Gynecol 1981;57(6 Suppl):76S-80S.

150. Kaufman RH, Korhonen MO, Strama T, Adam E, Kaplan A. Development of clear cell adenocarcinoma in DES-exposed offspring under observation. Obstet Gynecol 1982;145(3):375-7.

151. Kramer MS, Seltzer V, Krumholz B, Talebian F, Tedeschi C, Chen S. Diethylstilbestrol related clear-cell adenocarcinoma in women with initial examinations demonstrating on malignant disease. Obstet Gynecol 1987;69:868-71.

152. Lanier AP, Noller KL, Decker DG, Elveback LR, Kurland LT. Cancer and stilbesterol: a follow-up of 1,719 persons exposed to estrogens in utero and born 1943-59. Mayo Clin Proc 1973;48:793-9.

153. Mattingly RF, Stafl A. Cancer risk in diethylstilbestrol-exposed offspring. Am J Obstet Gynecol 1976;126:543-8.

154. Melnick S, Cole P, Anderson D, Herbst AL. Rates and risks of diethylstilbestrol-related clear cell adenocarcinoma of the vagina and cervix. Am J Eidemiol 1986;124(3):518-9.

155. Melnick S, Cole P, Anderson D, Herbst AL. Rates and risks of diethylstilbestrol-related clear cell adenocarcinoma of the vagina and cervix: an update. N Engl J Med 1987;316:514-6.

156. Monaghan JM, Sirisena LAW. Stilbestrol and vaginal clear-cell adenocarcinoma syndrome [case report]. Br Med J 1978;1;1588-90.

157. Noller KL, Decker DG, Lanier AP, Kurland LT. Clear cell adenocarcinoma of the cervix after maternal treatment with synthetic estrogens. Mayo Clin Proc 1972;47:629-30.

158. O'Brien PC, Noller KL, Robboy SJ, Barnes AB, Kaufman RH, Tilley BC, et al. Vaginal epithelial changes in young women enrolled in the National Cooperative Diethylstilbestrol Adenosis (DESAD) Project. Obstet Gynecol 1979;53:300-8.

159. Orr JW Jr, Shingleton HM, Gore H, Austin JM Jr, Hatch KD, Soong SJ. Cervical intraepithelial neoplasia associated with exposure to diethylstilbestrol in utero: a clinical and pathologic study. Obstet Gynecol 1981;58(1):75-82.

160. Robboy SJ, Truslow GY, Richart RM. Role of hormones including diethylstilbestrol (DES) in the pathogenesis of cervical and vaginal intraepithelial neoplasia. Gynecol Oncol 1981;12(2 pt 2):S98-S110.

161. Robboy SJ, Young RH, Welch WR, Truslow GY, Prat J, Herbst AL, et al. Atypical vaginal adenosis and cervical ectropion; association with clear cell adenocarcinoma in diethylstilbestrol-exposed offspring. Cancer 1984;54(5):869-75.

162. Robboy SJ, Kaufman RH, Prat J, Welch WR, Gaffey T, Scully RE, et al. Pathologic findings in young women enrolled in the National Cooperative Diethylstilbestrol Adenosis (DESAD) Project. Obstet Gynecol 1979;53:309.

163. Sandberg EC, Christian JC. Diethylstilbestrol-exposed monozygotic twins discordant for cervicovaginal clear cell adenocarcinoma. Am J Obstet Gynecol 1980;137:220-8.

164. Senekjian EK, Hubby M, Bell DA, Anderson D, Herbst AL. Clear cell adenocarcinoma (CCA) of the vagina and cervix in association with pregnancy. Gynecol Oncol 1986;24:207-19.

165. Senekjin EK, Frey KW, Stone C, Herbst AL. An evaluation of Stage II vaginal clear cell adenocarcinoma according to substages. Gynecol Oncol 1988;31(1):56-64.

166. Senekjin EK, Frey K, Herbst AL. Pelvic exenteration in clear cell adenocarcinoma of the vagina and cervix. Gynecol Oncol 1989;34(3):413-6.

167. Sharp GB, Cole P. Vaginal bleeding and diethylstilbestrol-exposure during pregnancy: relationship to genital tract clear cell adenocarcinoma and vaginal adenosis in daughters. Am J Obstet Gynecol 1990;162(4):994-1001.

168. Sharp GB, Cole P. Identification of risk factors for diethylstilbestrol-associated clear cell adenocarcinoma of the vagina: similarities to endometrial cancer. Am J Epidemiol 1991;134(11):1316-24.

169. Shapiro S, Slone D. The effect of exogenous female hormones of the fetus [review]. Epidemiol Rev 1979;1:110-23.

170. Veridiano NP, Tancer ML, Delke I, Gal D, Giannattasio C. Delayed onset of clear cell adenocarcinoma of the vagina in DES-exposed progeny. Obstet Gynecol 1981;57:395-8.

171. Vessey MP. Epidemiologic studies of the effects of diethylstilbestrol [review]. IARC Sci Publ 1989;96:335-48.

172. Wilkinson EJ. Pathology of the vagina [review]. Curr Opin Obstet Gynecol 1991;3(4):553-60.

173. Bornstein J, Adam E, Adler-Storthz K, Kaufman RH. Development of cervical and vaginal squamous cell neoplasia as a late consequence of in utero exposure to diethylstilbestrol. Obstet Gynecol Surv 1988;43(1):15-21.

174. Braun MM, Ahlbom A, Floderus B, Brinton LA, Hoover RN. Effect of twinship on incidence of cancer of the testis, breast, and other sites [Sweden]. Cancer Causes Control 1995;6:519-24.

175. Clark LC, Portier KM. Diethylstilbestrol and the risk of cancer. N Eng J Med 1979;300(5):263-4.

176. Ekbon A, Trichopoulos D, Adami HO, Hsieh CC, Lan SJ. Evidence of prenatal influences on breast cancer risk. Lancet 1992;340:1015-8.

177. Faber K, Jones M, Tarraza HM Jr. Invasive squamous cell carcinoma of the vagina in a diethylstilbestrol-exposed woman [case report]. Gynecol Oncol 1990;37(1):125-8.

178. Hatch EE, Herbst AL, Hoover RN, Noller KL, Adam E, Kaufman RH, et al. Incidence of squamous neoplasia of the cervix and vagina in women exposed prenatally to diethylstilbestrol (United States). Cancer Causes Control 2001;12(9):837-45.

179. Hatch EE, Palmer JR, Titus-Ernstoff L, Noller KL, Kaufman RH, Mittendorf R, et al. Cancer risk in women exposed to diethylstilbestrol in utero. JAMA 1998;280(7):630-4.

180. Henderson BE, Benton BD, Weaver PT, Linden G, Nolan JF. Stilbestrol and urogenital-tract cancer in adolescents and young adults. N Engl J Med 1973;288:354.

181. Kinlen LJ, Badaracco MA, Moffett J, Vessey MP. A survey of the use of estrogens during pregnancy in the United Kingdom and the genitourinary cancer mortality with incidence rates in young people in England and Wales. J Obstet Gynaecol Br Commonwlth 1974;81:849-55.

182. Lazarus KH. Maternal diethylstilbestrol and ovarian malignancy in offspring [letter]. Lancet 1984;53.

183. Mansi ML. Clear cell renal carcinoma in a pregnant DES-exposed patient [case report]. J Am Osteopath Assoc 1989;89(7):929-32.

184. Palmer JR, Hatch EE, Rosenberg CL, Hartge P, Kaufman RH, Titus-Ernstoff L, et al. Risk of breast cancer in women exposed to diethylstilbestrol in utero: preliminary results (United States). Cancer Causes Control 2002;13:753-8.

185. Potischman N, Troisi R In-utero and early life exposures in relation to risk of breast cancer. Cancer Causes Control 1999;1:561-73.

186. Robboy SJ, Szyfelbein WM, Goellner JR, Kaufman RH, Taft PD, Richard RM, et al. Dysplasia and cytologic findings in 4,589 young women enrolled in diethylstilbestrol-adenosis (DESAD) project. Am J Obstet Gynecol 1981;149(5):579-86.

187. Robboy SJ, Noller KL, O'Brien P, Kaufman RH, Townsend D, Barnes AB, et al. Increased incidence of cervical and vaginal dysplasia in 3,980 diethylstilbestrol-exposed young women. JAMA 1984;252(21):2979-83.

188. Thompson WK, Janerich DT. Maternal age at birth and risk of breast cancer in daughters. Epidemiology 1990;1:101-6.

189. Trichopoulos D. Hypothesis: Does breast cancer originate in utero? Lancet 1990;335(8695):939-40.

190. Vandrie DM, Puri S, Upton RT, DeMeester LJ. Adenosquamous carcinoma of cervix in a woman exposed to diethylstilbestrol in utero [case report]. Obstet Gynecol 1983;61(3 Suppl):S84-S7.

191. Verloop T, Rookus MA, van Leeuwen FE. Prevalence of gynecologic cancer in women exposed to diethylstilbestrol in utero [correspondence]. N Engl J Med 2000;342:1838-9.

192. Ambramsson L. On the investigation of men from infertile relations: a clinical study with special regard to anamnesis, physical examination, semen-, hormone- and chromosome analyses, from men with non-"normal" semen. Scand J Urol Nephrol 1988;Suppl 113:1-47.

193. Ambramsson L, Duchek M, Lundgren B. Conception rate for infertile couples: the importance of anamnesis and signs of genital disease in men with abnormal semen findings. Scand J Urol Nephrol 1989;23(3):165-71.

194. Andonian RW, Kessler R. Transplacental exposure to diethylstilbestrol in men. Urology 1979;13:276.

195. Bibbo M, Al-Naqeeb M, Baccarini I, Gill W, Newton M, Sleeper KM, et al. Follow-up study of male and female offspring of DES-treated mothers: a preliminary report. J Reprod Med 1975;15:29.

196. Bibbo M, Gill WB, Azizi F, Blough R, Fang VS, Rosenfield RL, et al. Follow-up study of male and female offspring of DES-exposed mothers. Obstet Gynecol 1977;49(1):1-7.

197. Bibbo M, Ali I, Al-Naqeeb M, Baccarini I, Climaco LA, Gill W, et al. Cytologic findings in female and male offspring of DES-treated mothers. Acta Cytol 1975;19:568.

198. Braun MM, Ahlbom A, Floderus B, Brinton LA, Hoover RN. Effect of twinship on incidence of cancer of the testis, breast, and other sites [Sweden]. Cancer Causes Control 1995;6:519-24.

199. Brown LM, Pottern LM, Hoover RN. Prenatal and perinatal risk factors for testicular cancer. Cancer Res 1986;46:4812-6.

200. Clark LC, Portier KM. Diethylstilbestrol and the risk of cancer. N Eng J Med 1979;300(5):263-4.

Back to Top

Contact Us | Site Map | Privacy Policy | Disclaimer | FOIA | Accessibility

CDC Home | Search | Health Topics A-Z



United States Department of Health and Human Services
Centers for Disease Control and Prevention